Determination of an aromatic retinoid and its main metabolite by high-performance liquid chromatography
Hänni, R.; Hervouet, D.; Busslinger, A.
Journal of Chromatography 162(4): 615-621
1979
ISSN/ISBN: 0021-9673 PMID: 528672 Document Number: 145876
Therapeutic success has been achieved with the retinoic acid analog, Ro 10-9359 [ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate], in psoriasis patients. The compound is both therapeutically effective in the mouse and prophylactically effective on epithelial tumors. The need to determine the bioavailability of different oral formulations of Ro 10-9359, to monitor clinically-effective plasma levels of patients undergoing oral retinoid therapy and to determine the pharmacokinetic parameters led to the development of a sensitive and specific assay for the determination of Ro 10-9359 and its pharmacologically-active main metabolite Ro 10-1670 in plasma. The assay allows the simultaneous determination of the drug Ro 10-9359 and its main metabolite Ro 10-1670 after extraction from plasma, using their UV absorbance at the absorption maximum of 360 nm. So far, more than 1000 plasma samples from rats, rabbits, dogs and humans have been analyzed using this assay.